J. Goldman & Co’s Agios Pharmaceuticals AGIO Stock Holding History

J. Goldman & Co’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-58,800	Closed	-$3.02M	–	332
2017 Q2	$3.02M	Buy	+58,800	New	+$3.01M	0.16%	145

Other funds holding AGIO

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

J. Goldman & Co's AGIO Position: Q3 2017 in Review

J. Goldman & Co sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 58,800 shares — an estimated $3.02M sold.

J. Goldman & Co first reported a position in AGIO in Q2 2017 and held it in 1 quarter. The position peaked at $3.02M in Q2 2017. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

J. Goldman & Co reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
J. Goldman & Co sold 58,800 Agios Pharmaceuticals shares in Q3 2017, an estimated $3.02M.
J. Goldman & Co first reported a position in Agios Pharmaceuticals in Q2 2017 and held it in 1 quarter.
J. Goldman & Co's Agios Pharmaceuticals position peaked at $3.02M in Q2 2017.
171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on J. Goldman & Co's 13F filing for Q3 2017, filed 14 Nov 2017.